Investing.com - Aslan Pharma ADR reported on Friday second quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of $-0.04 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.2 on revenue of $0.00.
Aslan Pharma ADR shares are down 23.21% from the beginning of the year and are trading at $0.860 , down-from-52-week-high.They are under-performing the Nasdaq which is down 17.33% from the start of the year.
Aslan Pharma ADR shares gained 24.62% in intra-day trade the report.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar